MAP2K7 and lung carcinoma: Dysregulated ncRNA have been shown to play a regulatory role in EGFR‐TKI resistance in lung cancer through modulating multiple signaling pathways, including the PI3K/AKT/mTOR, JAK/STAT, Ras/Raf/MEK/ERK signaling pathways.